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Abstract
Background—Atrial fibrillation (AF) is the most common cardiac dysrhythmia and contributes
significantly to health care expenditures. We sought to assess the frequency and predictors of
hospitalization in patients with AF.
Methods—The ORBIT-AF registry is a prospective, observational study of outpatients with AF
enrolled from June 29, 2010, to August 9, 2011. The current analysis included 9,484 participants
with 1-year follow-up. Multivariable, logistic regression was used to identify baseline
characteristics that were associated with first cause-specific hospitalization.
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Results—Overall, 31% of patients with AF studied (n = 2,963) had 1 or more hospitalizations
per year and 10% (n = 983) had 2 or more. The most common hospitalization cause was
cardiovascular (20 per 100 patient-years vs 3.3 bleeding vs 17 noncardiovascular, nonbleeding).
Compared with those not hospitalized, hospitalized patients were more likely to have concomitant
heart failure (42% vs 28%, P < .0001), higher mean CHADS2 (1 point for congestive heart failure,
hypertension, age ≥75, or diabetes; 2 points for prior stroke or transient ischemic attack) scores
(2.5 vs 2.2, P < .0001), and more symptoms (baseline European Heart Rhythm Association class
severe symptoms 18% vs 13%, P < .0001). In multivariable analysis, heart failure (adjusted hazard
ratio [HR] 1.57 for New York Heart Association III/IV vs none, P < .0001), heart rate at baseline
(adjusted HR 1.11 per 10-beats/min increase >66, P < .0001), and AF symptom class (adjusted HR
1.37 for European Heart Rhythm Association severe vs none, P < .0001) were the major predictors
of incident hospitalization.
Conclusions—Hospitalization is common in outpatients with AF and is independently predicted
by heart failure and AF symptoms. Improved symptom control, rate control, and comorbid
condition management should be evaluated as strategies to reduce health care use in these patients.
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Atrial fibrillation (AF) is the most common adult tachyarrhythmia, and its prevalence is
projected to at least double over the next 30 years.1 In addition to significant morbidity and
mortality,2,3 AF consequences include the expenditure of significant health care resources. It
is estimated that annual care for AF exceeds $6 billion in the United States.4 Most of these
costs result from inpatient care5 and are likely to grow. Some data suggest that AF
hospitalizations have increased to overtake myocardial infarction (MI) and heart failure as
the most common cause of cardiovascular admission globally.6-9
Although AF admissions are common, few studies have assessed all-cause and causespecific hospitalization rates among US patients with prevalent AF. The objectives of the
current study are as follows: (1) to assess the burden of hospitalization in patients with
prevalent AF, (2) to describe the cause-specific rates of hospitalization, and (3) to identify
baseline factors that significantly predict cause-specific hospitalization in US patients with
AF.
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Methods
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We used data from the ORBIT-AF study to assess hospitalization burden in patients with
AF. The ORBIT-AF study is a registry of US outpatients with AF, managed by primary care
physicians, cardiologists, and/or electrophysiologists. An adaptive design was used to recruit
a nationally representative sample of sites, with heterogeneity of geography and provider
type. Site management and study coordination were performed by the Duke Clinical
Research Institute. Sites enrolled consecutive patients, 18 years or older, with
electrocardiographically documented AF. Patients were followed up every 6 months for at
least 2 years and could not be included if AF was due to a reversible cause (eg, in the setting
of cardiac surgery or hyperthyroidism) or if life expectancy was less than 6 months. A Webbased case report form was used to gather data, and the primary sources were the patients'
medical record and treating physician.
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Data elements included patient demographics, medical history, components of AF history
(including prior treatment and symptoms), medical therapies, vital signs, laboratory and
imaging measures, and incident procedures and adverse events. Detailed medication data
were collected, including oral anticoagulation use, monitoring, and international normalized
ratio (INR) data (time in therapeutic range [TTR] is calculated based on the Rosendaal
method).10 End points included major adverse cardiovascular events (death, MI,
revascularization, stroke or systemic embolism, new heart failure, intervention for AF,
cardiac device implantation, or cardioversion), bleeding events, and cause-specific
hospitalization.
The present analysis includes 1-year data from ORBIT-AF, and all patients with at least 1
follow-up visit were included.
Statistical methods
Classification of hospitalizations—The total number of hospitalizations during followup in the study cohort was tabulated. Hospitalization cause was determined by the site
investigator and categorized as cardiovascular, bleeding, or other (noncardiovascular,
nonbleeding). All-cause mortality according to hospitalization burden was also calculated.
Additional details of the ORBIT-AF design and rationale have been previously described.11.
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Occurrence of first, cause-specific hospitalization (number of first hospitalizations per 100
patient-years) is presented overall and, for subgroups, by age, sex, heart failure status, and
CHADS2 score (1 point for congestive heart failure, hypertension, age ≥ 75, or diabetes; 2
points for prior stroke or transient ischemic attack). To compare rates within each subgroup,
we present P values using a Wald-test.
Characteristics of patients hospitalized—Patients were stratified by burden of
hospitalization: those with no hospitalizations and those with any hospitalization during the
follow-up period. Baseline characteristics were compared between these groups. Continuous
variables are presented as medians (Q1-Q3), and differences across 2 groupswere assessed
using the Wilcoxon rank sum test. Categorical variables are presented as counts
(proportions), and differences across hospitalization status were assessed using the χ2 test.
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To summarize the end points of (a) time to first all-cause hospitalization, (b) time to first
cardiovascular hospitalization, (c) time to first bleeding hospitalization, (d) time to first
other hospitalization, we display the number of patients at risk and the probability of no
hospitalization using a Kaplan-Meier plot. Similarly, probability of survival is shown by
hospitalization burden (none, any, 1, >1) using a Kaplan-Meier plot.
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In order to identify predictors of hospitalization in patients with AF, we created
multivariable models for the end points of (a) time to first all-cause hospitalization and (b)
time to first cardiovascular hospitalization. These results are presented as risk estimates
(hazard ratio [HR]) and corresponding 95% CI and P values using Cox regression with the
robust sandwich covariance estimates (accounting for correlation in the same site). The final
regression models for first all-cause and first cardiovascular hospitalization were developed
in the first imputed dataset based on selected risk factors from candidate baseline
characteristics using backward selection, with an α for exclusion of .05. All continuous
variables were tested for linearity, and nonlinear relationships were accounted for using
linear splines. Missing covariate data in the regression analysis (<15%) were handled by
multiple imputation using Markov Chain Monte Carlo and regression methods. Final
estimates and associated SEs reflect the combined analysis for 5 imputed data sets.
Discrimination of models was evaluated using c-index: values close to 1 indicate that the
model correctly identifies patients at greater risk compared with those at decreased risk.
All patients provided written, informed consent, and the ORBIT-AF registry was approved
by the Duke University Institutional Review Board. Each site also obtained institutional
review board approval pursuant to local regulations. All analyses of the aggregate, deidentified data were performed by the Duke Clinical Research Institute using SAS software
(version 9.3; SAS Institute, Cary, NC).

Results
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The overall ORBIT-AF population included 10,132 patients from 174 sites. After excluding
648 patients who did not have 6- or 12-month follow-up, this yielded a study population of
9,484 patients from 174 sites, enrolled from June 29, 2010, to August 9, 2011. During the
follow-up period, these patients experienced a total of 4,548 hospitalizations; 69% had no
hospitalization, 21% had exactly 1 hospitalization, and 10.4% had 2 or more hospitalizations
during the follow-up period (Figure 1). Overall, 2,963 (31%) patients had at least 1
hospitalization during follow-up; baseline characteristics, stratified by occurrence of any
hospitalization, are shown in Table I. Patients hospitalized were slightly older (median 76 vs
75 years, P < .0001), tended to be female (44% vs 42%, P = .046), and were more likely to
have a government payer (Medicare/Medicaid 73% vs 69%, P = .0002). Overall, patients
who experienced hospitalization were more likely to have significant cardiovascular risk
factors and noncardiovascular disease or comorbidities. Compared with patients not
hospitalized, those hospitalized were more likely to have concomitant cardiovascular
disease, including peripheral vascular disease, coronary artery disease, and cerebrovascular
disease (P < .0001 for each).
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Type of AF at baseline was not associated with hospitalization; however, patients
hospitalized had worse European Heart Rhythm Association (EHRA) symptom scores12
(18% with severe symptoms vs 13%, P < .0001) and higher CHADS2 scores (mean 2.5 vs
2.2, P < .0001). Use of any oral anticoagulant (78% vs 76%, 0.14) was not different across
patients based on hospitalization. Patients who experienced hospitalization were more likely
to have warfarin monitored by an anticoagulation clinic (35% vs 30%, P = .0001), had their
INR tested more frequently (4.7% monitored weekly vs 3.3%, P < .0001), and had lower
TTR (54% vs 65%, P < .0001). Use of both aspirin (47% vs 43%, P = .001) and clopidogrel
(9.5% vs 6.1%, P < .0001) was more common in patients with at least 1 hospitalization.
Characteristics of patients hospitalized multiple times during the follow-up period,
compared with those hospitalized none or one time, are shown in the Supplementary
Material (Table S1).
Causes of hospitalization
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Of 4,548 hospitalizations, 2,242 (49%) were for cardiovascular reasons, 345 (7.6%) were for
bleeding, and 1,961 (43%) were for other reasons. Cause-specific hospitalization rates, by
subgroup, are shown in Figure 2. Patients with heart failure had the highest rates of
hospitalization, for any cause, and proportions of cardiovascular, bleeding, and other
hospitalizations appeared stable across subgroups.
Mortality
Patients with any hospitalization during follow-up died at a rate of 10.81 events per 100
patient-years vs 1.92 deaths per 100 patient-years for patients without any hospitalization
during follow-up. Mortality was highest among patients hospitalized multiple times during
follow-up (14.8 per 100 patient-years), compared with 8.9 per 100 patient-years in patients
hospitalized once during follow-up.
Predictors of first incident hospitalization
All-cause first hospitalization occurred in at a rate of 38.8 per 100 patient-years
(cardiovascular: 20.1 per 100 patient-years; bleeding: 3.3 per 100 patient years; other: 17.5
per 100 patient-years). Kaplan-Meier curves for cause-specific first hospitalization,
calculated independently, are shown in Figure 3.
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In multivariable analysis, patients with significant heart failure at baseline (New York Heart
Association [NYHA] class II or III/IV) had the highest hazards of all-cause (adjusted HR
1.57 for NYHA III/IV, 95% CI 1.38-1.78) and cardiovascular (adjusted HR 1.72, 95% CI
1.46-2.04) hospitalization. Severe symptoms of AF by EHRA classification (those affecting
daily activities)12 were also significantly predictive of all-cause (adjusted HR 1.37 EHRA
severe symptoms, 95% CI 1.21-1.55), as was elevated heart rate at baseline (adjusted HR
1.11 per every 10-beats/min increase over 66, 95% CI 1.07-1.16). In addition, several
measures of AF chronicity and severity (eg, left-atrial size, AF type), as well as several
cardiovascular and noncardiovascular comorbidities, were all also significantly associated
with hospitalization. Complete model details for first all-cause hospitalization are shown in
Table II. In a model of first cardiovascular hospitalization, EHRA symptoms and heart rate
persisted as significant factors (see Supplementary Material).
Am Heart J. Author manuscript; available in PMC 2015 May 01.
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We subsequently modeled predictors of first all-cause and cardiovascular hospitalization
after excluding all patients with heart failure (n = 6,369 without heart failure; 67%). For both
all-cause and cardiovascular hospitalization, the major predictors were EHRA severe
symptoms (adjusted HR for all-cause hospitalization 1.42, 95% CI 1.19-1.69; adjusted HR
for cardiovascular hospitalization 1.96, 95% CI 1.57-2.45) and increasing heart rate
(adjusted HR per 10 beats/min for all-cause hospitalization 1.11, 95% CI 1.05-1.17; adjusted
HR per 10 beats/min for cardiovascular hospitalization 1.17, 95% CI 1.10-1.25).
Concomitant disease also contributed to risk of hospitalization among patients with AF
without heart failure (see Supplementary Material).

Discussion
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In this observational cohort of nearly 10,000 outpatients with AF, hospitalization is
common, with nearly 1 in 3 patients hospitalized within a year. Most hospitalizations in
patients with AF are for cardiovascular causes. Bleeding hospitalizations represented a
significant minority, and patients experiencing any hospitalization had lower TTR than did
those not hospitalized. Patients with highly symptomatic AF and heart failure are at
particular risk for hospitalization, and in multivariable analyses, severe heart failure, AF
symptoms, and elevated heart rate at baseline are significantly predictive of all-cause and
cardiovascular hospitalization.
Prior data regarding AF and hospitalization has primarily focused on the overall rates of
hospitalization AF; few data on the burden of hospitalization events among outpatients with
AF exist. Naccarelli et al13 used MarketScan and Medicare claims data to assess frequency
and cause of hospitalization in older Americans with AF. They found that more than onethird of patients with AF in Medicare had been hospitalized within 1 year, the majority for
cardiovascular causes. However, patient-level characteristics were not available to identify
factors most associated with hospitalization. Our data provide a more detailed look at such
patients and represent the largest, prospective model of hospitalization events for outpatients
with AF in the United States.
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Patients with preexisting heart failure were at highest risk for hospitalization in our cohort.
The combination of AF with heart failure is well known to be associated with particularly
high risk of morbidity and mortality.14 Furthermore, heart failure alone represents a
significant burden of inpatient hospitalization in the United States.15 Our data demonstrate
that preexisting heart failure in patients with AF significantly predicts subsequent
hospitalization, and such patients account for a disproportionate burden of hospitalizations
relative to other subgroups. This difference was largely driven by an excess of
cardiovascular hospitalizations in patients with heart failure. These data underscore the
urgent need and ongoing efforts to improve the treatment of heart failure and reduce the
frequency of recurrent hospitalization events in patients with concomitant AF and heart
failure.
However, hospitalization was also common in patients with AF without heart failure, with
more than 32 events per 100 patient-years. Additional independent predictors of
hospitalization included several factors related to the complexity of patients' AF. Patients
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with more severe symptoms by ERHA score and those who were not functionally
independent were at higher risk for hospitalization. Similarly, those treated with
antiarrhythmic drug therapy and patients requiring electrophysiology management were also
more likely to experience hospitalization. Lastly, left atrial enlargement, another measure of
AF chronicity, was also a significant predictor of hospitalization and is consistent with prior
data suggesting that left atrial measurements can predict subsequent cardiovascular events.16
When we modeled predictors of hospitalization in only these patients with AF without heart
failure, symptom status remained a major driver of events. Although this may seem intuitive
in retrospect, providers evaluating patients in clinic should recognize that symptom status is
a marker of high risk for hospitalization.
Increased heart rate at baseline was also significantly associated with hospitalization, both in
patients with and in patients without heart failure, and after adjustment for symptom class.
Whether increased heart rate is a marker for another process or whether better rate control
could mitigate hospitalization risk requires additional study.
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Taken together, these data support the need to investigate strategies to aggressively manage
patients with symptomatic and/or uncontrolled AF, in an effort to improve clinical
outcomes. Preliminary data suggest that catheter ablation for AF may reduce subsequent
health care use, in addition to improving symptoms.17,18 Although rhythm control strategies
have not been shown to improve survival, they do improve quality of life and decrease
hospitalization.19,20 Further studies of symptomatic management of AF are needed and may
yield reductions in hospitalization events for these patients.
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Although bleeding was the least common cause for hospitalization compared with
cardiovascular and other causes, it represented a relatively high proportion by historical
standards. It also represents a potentially modifiable cause of hospitalization. Most of this
cohort was treated with warfarin. In these patients, both measures of warfarin management
(frequency of INR testing and TTR) were significantly worse in patients experiencing
hospitalization. Although this may reflect interruption of warfarin in relation to the
hospitalization, it may also be a marker of instability leading to hospitalization. Regardless,
TTR has been closely correlated with both bleeding and thromboembolic events,21,22 and
strategies for maintaining high TTR are vital to the appropriate care of patients with AF
managed with warfarin. Whether better management of INR or use of novel anticoagulants
that do not require monitoring lead to reduced hospitalization remains to be proven.
Lastly, a significant number of hospitalizations in patients with AF were for
noncardiovascular, nonbleeding causes, and several significant comorbidities were
predictive of first all-cause hospitalization in multivariable analysis. Furthermore, patients
who were more frequently hospitalized had increasing rates of all-cause mortality. These
findings highlight the extensive, prevalent comorbidity present in an unselected population
of patients with AF and the associated risk. They also demonstrate the potential
opportunities for intervention in patients with significant disease burden, particularly those
who are hospitalized. Many patients have concomitant, morbidity-altering illnesses that will
increase their risk of adverse events and complicate management of AF. Treatment for the
patient with AF should be considered in the context of the patient's other medical problems,
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with the over-arching goal to minimize morbidity and mortality from all causes using
proven, evidence-based therapies.23
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Limitations
The data for this analysis are derived from an observational cohort of patients in clinical
practice with known AF and thus subject to the limitations inherent therein, including
sampling and/or reporting biases. Furthermore, conclusions regarding hospitalization cause
are limited in that the broad categories are investigator assigned and data regarding urgency
of admission (elective, emergent) are not available. Residual measured or unmeasured
confounding may influence some or all of these findings. Finally, although the ORBIT-AF
registry was inclusive, this population is older (consistent with the epidemiology of AF in
the United States) and overwhelmingly white (90%). Accordingly, these data may not be
entirely generalizable to younger patients, minority populations, or patients cared for in
settings that differ from those represented in ORBIT-AF.

Conclusions
NIH-PA Author Manuscript

Hospitalization is common in outpatients with AF, typically for cardiovascular or
noncardiovascular, non-bleeding causes. Patients experiencing hospitalization have more
comorbid disease, worse AF symptoms, and lower TTR. Heart failure symptom class and
AF symptom class, independently, are significant predictors of hospitalization. Improved
symptom control and heart failure/comorbid condition management should be targeted as
the primary strategies to reduce health care use in these patients.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Distribution of number of hospitalizations at 1 year of follow-up.
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Figure 2.

Rates of cause-specific hospitalization in patients with AF, by subgroup. P values presented are for the comparison of first allcause hospitalization between the subgroups. HF, heart failure.
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Figure 3.

Kaplan-Meier rates of first hospitalization, by cause.
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Table I

Baseline characteristics, by incident hospitalization
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Overall
(n = 9484)

No hospitalization
(n = 6521)

Any hospitalization
(n = 2963)

Age (y)

75 (67–82)

75 (67–81)

76 (68–82)

Female

43

42

44

White

90

89

91

Black or African American

4.7

4.8

4.6

Hispanic

4.1

4.3

3.6

Other

1.4

1.5

1.2

Race

P
<.0001
.046
.17

Health insurance status

.0002

Medicare or Medicaid

70

69

73

Private

25

26

22

Other

NIH-PA Author Manuscript

4.7

4.8

4.4

Hypertension

83

82

85

Hyperlipidemia

73

72

74

.12

Diabetes

29

27

35

<.0001

.0006

Peripheral vascular disease

13

12

17

<.0001

Coronary artery disease

33

29

39

<.0001

None

67

72

57

NYHA I

10

9.9

11

NYHA II

15

13

20

NYHA III/IV

7.4

5.5

11

15

14

17

>50%

70

72

68

40%–50%

6.3

5.8

7.5

30%–40%

8.9

7.9

11

Heart failure

<.0001

Prior cerebrovascular events (stroke or TIA)
Left ventricular ejection fraction

<30%

<.0001

4.3

3.6

5.7

67 (53–82)

68 (55–83)

64 (50–79)

4.4

4.3

4.7

Paroxysmal

51

51

50

Persistent

17

17

17

Long-standing persistent

28

28

29

Calculated glomerular filtration rate (mL/min per 1.73 m2
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AF type at baseline
New onset

<.0001
0.54

EHRA symptom class

<.0001

None

38

40

33

Mild

45

45

46

Severe

15

13

18

Disabling

1.8

1.8

1.8

2.3 (1.3)

2.2 (1.3)

2.5 (1.3)

CHADS2 score, mean (SD)

<.0001
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Overall
(n = 9484)

No hospitalization
(n = 6521)

Any hospitalization
(n = 2963)

Antiarrhythmic therapy at baseline

29

28

31

.003

Any oral anticoagulant

77

76

78

.14

Oral anticoagulant*

P

.39

None

23

24

22

Warfarin

72

71

73

Dabigatran

4.8

4.9

4.8

62 (41–80)

65 (45–83)

54 (36–73)

Percent time INR <2, median (IQR)

19 (4–37)

17 (0–34)

25 (9–43)

<.0001

Percent time INR >3, median (IQR)

9 (0–23)

9 (0–22)

12 (0–26)

<.0001

Percent time in therapeutic range (INR 2-3), median (IQR)

<.0001

Values are presented as % or median (interquartile range), unless noted otherwise. Time in therapeutic range was calculated using the Rosendaal
method.10
Abbreviations: TIA, transient ischemic attack; IQR, interquartile range.
*

No patients were on rivaroxaban or apixaban at baseline.
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Table II

Predictors of first all-cause hospitalization
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Adjusted HR
(95% CI)

t Value

P

NYHA class III/IV

1.57 (1.38–1.78)

6.80

<.0001

Increased heart rate (>66), per 10 beats/min

1.11 (1.07–1.16)

5.36

<.0001

NYHA class II

1.35 (1.21–1.51)

5.28

<.0001

EHRA severe

1.37 (1.21–1.55)

5.09

<.0001

NIH-PA Author Manuscript

COPD

1.23 (1.12–1.34)

4.37

<.0001

Prior treatment with antiarrhythmic drug

1.16 (1.07–1.27)

3.62

.0003

Prior MI

1.17 (1.07–1.29)

3.28

.001

Peripheral vascular disease

1.18 (1.07–1.31)

3.31

.0009

History of PCI

1.18 (1.07–1.30)

3.34

.0008

Diabetes

1.13 (1.05–1.22)

3.22

.001

NYHA class I

1.21 (1.07–1.36)

3.13

.002

EHRA mild

1.16 (1.06–1.28)

3.22

.001

Not living independently

1.24 (1.09–1.42)

3.29

.001

Obstructive sleep apnea

1.16 (1.05–1.28)

2.94

.003

Severe LAE

1.21 (1.07–1.36)

3.03

.003

Anemia

1.15 (1.05–1.26)

2.95

.003

Hypothyroidism

1.11 (1.03–1.20)

2.77

.006

Cancer

1.12 (1.03–1.21)

2.70

.007

Frailty

1.20 (1.05–1.39)

2.61

.009

Moderate LAE

1.11 (0.99–1.25)

1.73

.08

Mild LAE

1.07 (0.94–1.20)

1.02

.3

EHRA disabling symptoms

1.06 (0.78–1.45)

0.39

.7

Increased heart rate (≤66), per 10 beats/min

0.89 (0.80–0.99)

−2.07

.04

Increased diastolic blood pressure, per 10 mm Hg

0.95 (0.91–0.99)

−2.42

.02

Increased hematocrit, per 10%

0.83 (0.76–0.90)

−4.40

<.0001

c Index = 0.63.
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Abbreviations: COPD, chronic obstructive lung disease; PCI, percutaneous coronary intervention; CHF, congestive heart failure; LAE, left atrial
enlargement.
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